Logo - International Journal of Pharmaceutical Compounding

Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution)

Author(s):  Voudrie Mark A II, Allen D Brett

Issue:  Jan/Feb 2010 - Pediatrics and Wellness
View All Articles in Issue

Abstract:  Oseltamivir (Tamiflu) is widely prescribed to treat and prevent influenza virus A, influenza virus B, and H1N1 Flu. It is manufactured by Roche in 75- mg capsules. The need for other administration options for patients who cannot take capsules and cannot use suspending agents which contain alcohol, sorbitol, or preservatives has led to the compounding of oseltamivir into three suspending vehicles that do not contain these chemicals. All three contain neither alcohol nor sorbitol; the third also has no preservatives, a distinct advantage for special patient situations. The objective of this study was to determine the stability of oseltamivir in three different suspending agents: SyrSpend SF, Cherry Syrup, and SyrSpend SF (for reconstitution). The studied samples were compounded into 15-mg/mL suspensions and stored in low actinic plastic prescription bottles at temperatures between 2°C and 8°C. Triplicate samples were assayed at time intervals out to 30 days by a stability-indicating high-performance liqu

Related Keywords: Mark A Voudrie II, BS, D. Brett Allen, BS, oseltamivir phosphate, influenza, oral liquid preparations, children, stability, storage, alcohol, sorbitol, preservatives

Related Categories: EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, INFECTIOUS DISEASE, STORAGE

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=3080

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products